If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Research Regulatory News (EDEN)

Share Price Information for Eden Research (EDEN)

Share Price is delayed by 15 minutes
Get Live Data
2.90    0.00 (0.00%)
Bid:
2.80
Ask:
3.00
Spread: 0.20 (7.143%)
Market Cap: £23.30m
EDEN Live PriceLast checked at - London Stock Exchange

Intraday Eden Research Share Chart

Holding(s) in Company

9 Oct 2023 16:44

RNS Number : 4645P
Eden Research plc
09 October 2023
Β 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB0001646941

Issuer Name

EDEN RESEARCH PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights; An event changing the breakdown of voting rights

3. Details of person subject to the notification obligation

Name

Octopus Investments Limited

City of registered office (if applicable)

London

Country of registered office (if applicable)

England

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

Β 

City of registered office (if applicable)

Β 

Country of registered office (if applicable)

Β 

5. Date on which the threshold was crossed or reached

06-Oct-2023

6. Date on which Issuer notified

09-Oct-2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

7.790000

0.000000

7.790000

41551047

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB0001646941

0

41551047

0.000000

7.790000

Sub Total 8.A

41551047

7.790000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

Β 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Β 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Octopus Capital Limited

Octopus Investments Limited

7.790000

0.000000

7.790000%

10. In case of proxy voting

Name of the proxy holder

Β 

The number and % of voting rights held

Β 

The date until which the voting rights will be held

Β 

11. Additional Information

Β 

12. Date of Completion

09/10/2023

13. Place Of Completion

33 Holborn, London, EC1N 2HT

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
HOLUPGWCUUPWGAB
Date   Source Headline
25th Jun 20267:00 amRNS2026 Green Economy Mark
27th May 20267:00 amRNSDirectorate change
28th Apr 20267:00 amRNSTrading Update
16th Apr 20262:59 pmRNSHolding(s) in Company
14th Apr 20264:30 pmRNSHolding(s) in Company
14th Apr 20263:31 pmRNSHolding(s) in Company
13th Apr 202611:31 amRNSHolding(s) in Company
10th Apr 20267:00 amRNSCompletion of Conditional Placing and TVR
8th Apr 202612:10 pmRNSSatisfaction of Conditions of Conditional Placing
2nd Apr 20267:00 amRNSThymolflex EPA approval
19th Feb 20263:59 pmRNSHolding(s) in Company
19th Feb 20261:29 pmRNSHolding(s) in Company
18th Feb 20269:40 amRNSResult of General Meeting and Total Voting Rights
5th Feb 20262:50 pmRNSResult of Retail Offer
2nd Feb 20261:01 pmRNSLaunch of Retail Offer
2nd Feb 202612:57 pmRNSProposed Placing and Subscription
9th Jan 20267:00 amRNSNovellus+ Regulatory Authorisation in Chile
7th Jan 20267:00 amRNSMevalone Label Extension in France
18th Dec 20257:00 amRNSAppointment of Syngenta as Distribution Partner
20th Nov 20257:00 amRNS3LOGY Label Extension in Italy
17th Nov 20257:00 amRNSEcovelex 2025 Approval in Italy
17th Sep 20259:45 amRNSDirector/PDMR Shareholdings
17th Sep 20258:36 amRNSDirector/PDMR Shareholdings
17th Sep 20257:00 amRNSHalf Yearly Report
15th Sep 20257:00 amRNSNotice of Results
18th Jun 20251:40 pmRNSResult of AGM
18th Jun 20257:00 amRNSAGM Statement
16th Jun 20257:00 amRNSEcovelex Partnership with Royal Holloway
27th May 20255:22 pmRNSNotice of AGM
13th May 20257:00 amRNSMevalone Approval in California - Powdery Mildew
9th May 20257:00 amRNS-RInvestor Presentation via Investor Meet Company
6th May 202512:08 pmRNSHolding(s) in Company
6th May 20257:00 amRNSPreliminary results for the year ended 31 Dec 2024
10th Apr 20257:00 amRNSThymol Supply Agreement For Bee Health
1st Apr 202510:08 amRNSDirector/PDMR Shareholdings
24th Mar 20257:00 amRNSAppointment of Distribution Partner in Kenya
10th Mar 20257:00 amRNSAppointment of Joint Broker
5th Mar 202512:52 pmRNSDirector/PDMR Shareholding
5th Mar 20257:00 amRNSDirector/PDMR Shareholding
4th Mar 20252:13 pmRNSDirector/PDMR Shareholdings
6th Feb 20252:08 pmRNSDirector/PDMR Shareholding
5th Feb 20257:00 amRNS-RInvestor Presentation via Investor Meet Company
28th Jan 202510:36 amRNSDirector/PDMR Shareholdings
13th Jan 20257:12 amRNSTrading Update
20th Dec 20247:00 amRNSRegulatory approval for Novellus+ in Mexico
16th Dec 20247:00 amRNSAppointment of Distributor in Austria
11th Dec 20247:00 amRNSMevalone Organic Input Registration in Germany
7th Nov 20247:01 amRNSTrading Update
7th Nov 20247:00 amRNSEcovelex Approval in Italy
8th Oct 202411:24 amRNSOTCQB exchange update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.